Trial Profile
A 54-week, Open-label, Multicenter Study to Assess the Long-term Safety and Tolerability of the Combination of Aliskiren 300 mg /Valsartan 320 mg in Patients With Essential Hypertension Followed by a 26 Week Open-label Extension to Assess the Long-term Safety and Tolerability of the Triple Combination of Aliskiren/Valsartan/Hydrochlorothiazide(HCTZ).
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Sep 2021
Price :
$35
*
At a glance
- Drugs Aliskiren (Primary) ; Aliskiren/valsartan (Primary) ; Valsartan (Primary) ; Hydrochlorothiazide
- Indications Essential hypertension
- Focus Adverse reactions; Registrational
- Sponsors Novartis; Novartis Pharmaceuticals Corporation
- 09 May 2011 Actual trial end date changed from Mar 2008 to Jul 2008 as reported by ClinicalTrials.gov.
- 09 May 2011 Additional trial location (Netherlands) added as reported by ClinicalTrials.gov.
- 16 Jun 2009 Results presented at the 19th European Meeting on Hypertension